leadf
logo-loader
viewANGLE PLC

ANGLE says liquid biopsy system proves effective in helping scientists assess treatment options for men with advanced prostate cancer

"ANGLE's Parsortix system demonstrates a straightforward and scalable approach, which can be used to investigate novel candidate biomarkers and therapeutic targets in advanced disease," said Amir Goldkorn, whose team at the University of Southern California used the device in their research

ANGLE PLC -

ANGLE PLC (LON:AGL) (OTCQX:ANPCY) has said its liquid biopsy system provides a “straightforward and scalable approach” to analysing and assessing treatment options for men with advanced prostate cancer.

That was the conclusion of associate professor Amir Goldkorn, whose team at the University of Southern California, used ANGLE’s Parsortix device as part of its workflow to decide which drugs or drug combinations to give patients.

Partsortix harvests the tell-tale signs of cancer called circulating tumour cells (CTCs) so that they can then be assessed. It offers an alternative to physical biopsies, which are invasive and painful, and antibody-based methods of capturing of cells.

The ANGLE technology was deployed in a process called transcriptomic profiling. This is the method by which cancer cells are analysed to identify how the patient's cancer is developing and evading the immune system. It allows decisions to be made as to which drug treatments may be most effective for that patient at that time.

Standard tissue biopsy reflects only a single metastatic site at a single point in time, whereas CTCs harvested using Parsortix allows an analysis of cells from potentially multiple sites.

“This approach enables personalised medicine and addresses the major problem of identifying the right drug at the right time as most drugs only work for a proportion of patients and a one size fits all approach is limited in its effectiveness,” ANGLE.

Other advantages of using Parsortix included the high cell enrichment levels; that samples required minimal manipulation; cells were free of antibodies or magnetic beads; allowed rapid, flexible use.

"University of Southern California's workflow using the Parsortix system is a significant step forward as it demonstrates a simple, effective way to utilise the harvested CTCs for gene expression analysis to advise drug selection decisions and to provide a dynamic analysis of the effectiveness of treatment,” Andrew Newland, ANGLE’s chief executive said in a statement.

“We believe the applicability of the workflow will not be limited to prostate cancer and may extend to most, if not all, solid tumour cancer types."

Quick facts: ANGLE PLC

Price: 48.375 GBX

AIM:AGL
Market: AIM
Market Cap: £83.59 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

ANGLE PLC's Andrew Newland on 'breakthrough in culturing CTCs'

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), tells Proactive's Andrew Scott that researchers using their Parsortix device for capturing circulating tumour cells may have found another “clear high value application” for the system. Not only have they discovered a method of...

on 19/4/18

2 min read